Iron storage disease: Facts, fiction and progress

Blood Cells, Molecules, and Diseases

Volumn 39, Issue 2, 2007, Pages 140-147

  Beutler, Ernest ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Ferritin; Hemochromatosis; Hepcidin; Penetrance

Indexed keywords

BETA 2 MICROGLOBULIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BONE MORPHOGENETIC PROTEIN; CD71 ANTIGEN; CERULOPLASMIN; CHELATING AGENT; CYTOCHROME B; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERROPORTIN 1; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOJUVELIN; HEPCIDIN; HFE PROTEIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN; TRANSFERRIN RECEPTOR 2; WNT2 PROTEIN;

AGRANULOCYTOSIS; ANEMIA; ARTICLE; CHELATION THERAPY; CONGENITAL DYSERYTHROPOIETIC ANEMIA; EUROPE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEMOCHROMATOSIS; HEMOSIDEROSIS; HOMOZYGOSITY; HUMAN; IRON ABSORPTION; IRON OVERLOAD; LIVER FUNCTION TEST; MYELODYSPLASIA; NONHUMAN; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL; RARE DISEASE; RASH; SIDE EFFECT; THALASSEMIA;

ANTIMICROBIAL CATIONIC PEPTIDES; CATION TRANSPORT PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HEMOCHROMATOSIS; HUMANS; PENETRANCE;

EID: 34547185474     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.03.009     Document Type: Article

References (93)

1. McCance R.A., and Widdowson E.M. Absorption and excretion of iron. Lancet 2 (1937) 680-684
2. Beutler E., Fairbanks V.F., and Fahey J.L. Clinical Disorders of Iron Metabolism (1963), Grune & Stratton, Inc., New York
3. Hahn P.F., Bale W.F., Ross J.F., et al. Radioactive iron absorption by gastro-intestinal tract: influence of anemia, anoxia, and antecedent feeding. J. Exp. Med. 78 (1943) 169-188
4. Beutler E. History of iron in medicine. Blood Cells Mol. Diseases 29 (2002) 297-308
5. Nemeth E., and Ganz T. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr. 26 (2006) 323-342
6. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
7. Nicolas G., Bennoun M., Devaux I., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8780-8785
8. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276 (2001) 7811-7819
9. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet. 36 (2004) 77-82
10. Nemeth E., Roetto A., Garozzo G., et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood 105 (2005) 1803-1806
11. Goswami T., and Andrews N.C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J. Biol. Chem. 281 (2006) 28494-28498
12. Truksa J., Peng H., Gelbart T., et al. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10289-10293
13. Flanagan J.M., Peng H., Wang L., et al. Soluble transferrin receptor-1 levels in mice do not affect iron absorption. Acta Haematol. (Basel) 116 (2006) 249-254
14. Weizer-Stern O., Adamsky K., Amariglio N., et al. Down regulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Blood 108 (2006) 447a
15. Lin L., Goldberg Y.P., and Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 106 (2005) 2884-2889
16. Zhang A.S., Anderson S.A., Meyers K.R., et al. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J. Biol. Chem. (2007) M608788200
17. Sheldon J.H. Haemochromatosis (1935), Oxford University Press, London
18. Davis W.D., and Arrowsmith W.R. The effect of repeated phlebotomies in hemochromatosis. J. Lab. Clin. Med. 39 (1952) 526-532
19. Finch C. Iron metabolism in hemochromatosis. J. Clin. Invest. 28 (1949) 780
20. Simon M., Pawlotsky Y., Bourel M., et al. Hémochromatose idiopathique: maladie associée à l'antigène tissulaire. Nouv. Presse Med. 4 (1975) 1432
21. Simon M., Bourel R., Fauchet R., and Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic hemochromatosis. Gut 17 (1976) 332-334
22. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13 (1996) 399-408
23. Adams P.C., Gregor J.C., Kertesz A.E., and Valberg L.S. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology 109 (1995) 177-188
24. Yapp T.R., Eijkelkamp E.J., and Powell L.W. Population screening for HFE-associated haemochromatosis: should we have to pay for our genes?. Intern. Med. J. 31 (2001) 48-52
25. Allen K., and Williamson R. Screening for hereditary haemochromatosis should be implemented now. BMJ 320 (2000) 183-184
26. Adams P., Brissot P., and Powell L. EASL International Consensus Conference on Haemochromatosis: Part II. Expert document. J. Hepatol. 33 (2000) 487-496
27. Beutler E., Felitti V., Gelbart T., and Ho N. The effect of HFE genotypes in patients attending a health appraisal clinic. Ann. Intern. Med. 133 (2000) 329-337
28. Beutler E., Felitti V.J., Koziol J.A., et al. Penetrance of the 845G->A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
29. Waalen J., Felitti V., Gelbart T., et al. Prevalence of hemochromatosis-related symptoms in homozygotes for the C282Y mutation of the HFE gene. Mayo Clin. Proc. 77 (2002) 522-530
30. Waalen J., Felitti V.J., Gelbart T., et al. Penetrance of hemochromatosis. Blood Cells Mol. Diseases 29 (2002) 418-432
31. Beutler E. Disorders of iron metabolism. In: Lichtman M.A., Beutler E., Kipps T.J., Seligsohn U., Kaushansky K., and Prchal J. (Eds). Williams Hematology (2006), McGraw-Hill, New York 511-553
32. Cox T., Rochette J., Camaschella C., et al. Clinical haemochromatosis in HFE carriers. Lancet 360 (2002) 412
33. Allen K.J., Warner B., and Delatycki M.B. Clinical haemochromatosis in HFE carriers. Lancet 360 (2002) 412-413
34. Åsberg A., Hveem K., Thorstensen K., et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand. J. Gastroenterol. 36 (2001) 1108-1115
35. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med. 352 (2005) 1769-1778
36. Beutler E. Discrepancies between genotype and phenotype in hematology: an important frontier. Blood 98 (2001) 2597-2602
37. Whitelaw E., and Martin D.I. Retrotransposons as epigenetic mediators of phenotypic variation in mammals. Nat. Genet. 27 (2001) 361-365
38. MacDonald R.A. Idiopathic hemochromatosis: a variant of portal cirrhosis and idiopathic hemosiderosis. Arch. Intern. Med. 107 (1961) 606-616
39. MacDonald R.A. Idiopathic hemochromatosis. Genetic or acquired?. Arch. Intern. Med. 112 (1963) 82-88
40. Milder M.S., Cook J.D., Stray S., and Finch C.A. Idiopathic hemochromatosis, an interim report. Medicine 59 (1980) 34-49
41. Scotet V., Merour M.C., Mercier A.Y., et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am. J. Epidemiol. 158 (2003) 129-134
42. Fletcher L.M., Dixon J.L., Purdie D.M., et al. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122 (2002) 281-289
43. Flanagan J.M., Peng H., and Beutler E. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcohol Clin. Exp. Res. 31 (2006) 138-143
44. Harrison-Findik D.D., Schafer D., Klein E., et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 281 (2006) 22974-22982
45. Cade J.E., Moreton J.A., O'hara B., et al. Diet and genetic factors associated with iron status in middle-aged women. Am. J. Clin. Nutr. 82 (2005) 813-820
46. van der A D.L., Peeters P.H., Grobbee D.E., et al. HFE genotypes and dietary heme iron: No evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr. Metab. Cardiovasc. Dis. 16 (2006) 60-68
47. 2 microglobulin deficient hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9263-9265
48. Beutler E., Waalen J., and Gelbart T. Chronic inflammation does not appear to modify the homozygous hereditary hemochromatosis phenotype. Blood Cells Mol. Diseases 35 (2005) 326-327
49. Dubois S., and Kearney D.J. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am. J. Gastroenterol. 100 (2005) 453-459
50. Hershko C. A hematologist's view of unexplained iron deficiency anemia in males: impact of Helicobacter pylori eradication. Blood Cells Mol. Diseases 38 (2007) 45-53
51. Beutler E., and Gelbart T. Helicobacter pylori infection and HFE hemochromatosis. Blood Cells Mol. Diseases 37 (2006) 188-191
52. Beutler E., Gelbart T., and Lee P. Haptoglobin polymorphism and iron homeostasis. Clin. Chem. 48 (2002) 2232-2235
53. Beutler E., Beutler L., Lee P.L., and Barton J.C. The mitochondrial NT 16189 polymorphism and hereditary hemochromatosis. Blood Cells Mol. Diseases 33 (2004) 344-345
54. Lee P.L., Ho N.J., Olson R., and Beutler E. The effect of transferrin polymorphisms on iron metabolism. Blood Cells Mol. Diseases 25 (1999) 374-379
55. Lee P.L., Halloran C., and Beutler E. Polymorphisms in the transferrin 5′ flanking region associated with differences in total iron binding capacity: possible implications in iron homeostasis. Blood Cells Mol. Diseases 27 (2001) 539-548
56. Lee P.L., Gelbart T., West C., et al. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol. Diseases 27 (2001) 783-802
57. Lee P.L., Halloran C., West C., and Beutler E. Mutation analysis of the transferrin receptor-2 gene in patients with iron overload. Blood Cells Mol. Diseases 27 (2001) 285-289
58. Lee P.L., Gelbart T., West C., et al. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol. Diseases 29 (2002) 471-487
59. Krayenbuehl P.A., Maly F.E., Hersberger M., et al. Tumor necrosis factor-{alpha} -308G>A polymorphism modulates iron accumulation in patients with hereditary hemochromatosis. Clin. Chem. 52 8 (2006) 1552-1558
60. Jacolot S., Le Gac G., Scotet V., et al. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 103 (2004) 2835-2840
61. Le Gac G., Scotet V., Ka C., et al. 'The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum. Mol. Genet. 13 (2004) 1913-1918
62. Livesey K.J., Wimhurst V.L., Carter K., et al. The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. J. Med. Genet. 41 (2004) 6-10
63. Valenti L., Conte D., Piperno A., et al. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J. Med. Genet. 41 (2004) 946-950
64. Carter K., Bowen D.J., McCune C.A., and Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br. J. Haematol. 122 (2003) 326-332
65. Distante S., Elmberg M., Haug K.B.F., et al. Tumour necrosis factor alpha and its promoter polymorphisms' role in the phenotypic expression of hemochromatosis. Scand. J. Gastroenterol. 38 (2003) 871-877
66. Merryweather-Clarke A.T., Cadet E., Bomford A., et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum. Mol. Genet. 12 (2003) 2241-2247
67. Delanghe J.R., and Langlois M.R. Haptoglobin polymorphism and body iron stores. Clin. Chem. Lab. Med. 40 (2002) 212-216
68. Nicolas G., Andrews N.C., Kahn A., and Vaulont S. Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice. Blood 103 (2004) 2841-2843
69. Whiting P., Fletcher L., Dixon J., et al. Concordance of iron indices in homozygote and heterozygote sibling pairs in hemochromatosis families: implications for family screening. J. Hepatol. 37 (2002) 309
70. Niederau C., Fischer R., Sonnenberg A., et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N. Engl. J. Med. 313 (1985) 1256-1262
71. Niederau C., Fischer R., Puerschel A., et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 (1996) 1107-1119
72. Waalen J., Nordestgaard B.G., and Beutler E. The penetrance of hereditary hemochromatosis. Best Pract. Res. Clin. Haematol. 18 (2005) 203-220
73. Williams R., Smith P.M., Spicer E.J.F., et al. Venesection therapy in idiopathic haemochromatosis. Q. J. Med. 38 (1969) 1-16
74. Fischer R. Klinik und Therapie der idiopathischen Hämochromatose. Erfahrungen bei 51 eigenen Fllen. Leber Magen Darm 6 (1976) 316-329
75. Knauer C.M., Gamble C.N., and Monroe L.S. The reversal of hemochromatotic cirrhosis by multiple phlebotomies. Report of a case. Gastroenterology 49 (1965) 667-671
76. Falize L., Guillygomarc'h A., Perrin M., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44 (2006) 472-477
77. Morrison E.D., Brandhagen D.J., Phatak P.D., et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann. Intern. Med. 138 (2003) 627-633
78. Beaton M., Guyader D., Deugnier Y., et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 36 (2002) 673-678
79. Guyader D., Jacquelinet C., Moirand R., et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115 (1998) 929-936
80. Andersen R.V., Tybjaerg-Hansen A., Appleyard M., et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103 (2004) 2914-2919
81. Beutler E. Natural history of hemochromatosis. Mayo Clin. Proc. 79 (2004) 305-306
82. Olynyk J.K., Hagan S.E., Cullen D.J., et al. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin. Proc. 79 (2004) 309-313
83. Bomford A., and Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q. J. Med. 180 (1976) 611-623
84. Beaton M., and Adams P.C. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can. J. Gastroenterol. 20 (2006) 257-260
85. Fracanzani A.L., Conte D., Fraquelli M., et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33 (2001) 647-651
86. Blumberg R.S., Chopra S., Ibrahim R., et al. Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. Gastroenterology 95 (1988) 1399-1402
87. Britto M.R.C., Thomas L.A., Balaratnam N., et al. Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand. J. Gastroenterol. 35 (2000) 889-893
88. Brage A., Tome S., Figueruela B., et al. Hepatoma in a 40-year old male with hereditary hemochromatosis in the absence of cirrhosis. Implications of molecular diagnosis. Rev. Esp. Enferm. Dig. 94 (2002) 493-499
89. Dale S.P., Aithal G.P., Thomas J.A., et al. Risk of hepatocellular carcinoma associated with genetic haemochromatosis in the absence of cirrhosis: a retrospective cohort study. J. Hepatol. 44 (2006) S88
90. Willis G., Bardsley V., Fellows I.W., et al. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. BMC Gastroenterol. 5 (2005) 17
91. Powell L.W., Dixon J.L., Ramm G.A., et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch. Intern. Med. 166 (2006) 294-301
92. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassen a major: new data, new questions. Blood 107 (2006) 3436-3441
93. Truksa J., Lee P., Flanagan J., and Beutler E. Different regulatory elements are required for response of hepcidin to IL-6 and BMP-9. Br. J. Haematol. (2007) (in press)